Neurotoxicities associated with immune checkpoint inhibitor therapy

[1] Larkin J(2015)Combined nivolumab and ipilimumab or monotherapy in untreated melanoma N Engl J Med 373 23-34

[2] Chiarion-Sileni V(2016)Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer N Engl J Med 375 1823-1833

[3] Gonzalez R(2015)Nivolumab versus everolimus in advanced renal-cell carcinoma N Engl J Med 373 1803-1813

[4] Grob JJ(2018)Trial watch: The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors Nat Rev Drug Discov 17 854-855

[5] Cowey CL(2012)The blockade of immune checkpoints in cancer immunotherapy Nat Rev Cancer 12 252-264

[6] Lao CD(2018)Immune-related adverse events associated with immune checkpoint blockade N Engl J Med 378 158-168

[7] Schadendorf D(2017)Neurological adverse events associated with immune checkpoint inhibitors: review of the literature Eur J Cancer 73 1-8

[8] Dummer R(2017)Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors Eur J Cancer 82 128-136

[9] Smylie M(2017)Neurological toxicities associated with immune-checkpoint inhibitors Curr Opin Neurol 30 659-668

[10] Rutkowski P(2018)Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis JAMA Oncol 4 173-182

[1] Larkin J(2015)Combined nivolumab and ipilimumab or monotherapy in untreated melanoma N Engl J Med 373 23-34

[2] Chiarion-Sileni V(2016)Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer N Engl J Med 375 1823-1833

[3] Gonzalez R(2015)Nivolumab versus everolimus in advanced renal-cell carcinoma N Engl J Med 373 1803-1813

[4] Grob JJ(2018)Trial watch: The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors Nat Rev Drug Discov 17 854-855

[5] Cowey CL(2012)The blockade of immune checkpoints in cancer immunotherapy Nat Rev Cancer 12 252-264

[6] Lao CD(2018)Immune-related adverse events associated with immune checkpoint blockade N Engl J Med 378 158-168

[7] Schadendorf D(2017)Neurological adverse events associated with immune checkpoint inhibitors: review of the literature Eur J Cancer 73 1-8

[8] Dummer R(2017)Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors Eur J Cancer 82 128-136

[9] Smylie M(2017)Neurological toxicities associated with immune-checkpoint inhibitors Curr Opin Neurol 30 659-668

[10] Rutkowski P(2018)Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis JAMA Oncol 4 173-182